Search company, investor...
KaloCyte company logo
Analyst Briefing Submitted

Founded Year



Unattributed | Alive

Total Raised




About KaloCyte

KaloCyte is developing a freeze-dried blood substitute that could be reconstituted and administered to treat traumatic hemorrhage when banked blood is unavailable or undesirable. KaloCyte's ErythroMer red cell substitute is human hemoglobin encapsulated in a synthetic polymer shell. Its design precisely emulates red blood cell oxygen binding/release. The company was founded in 2016 and is based in Blatimore, Maryland.

KaloCyte Headquarters Location

670 W Baltimore St HSRF III, 8th Floor

Baltimore, Maryland, 21201,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

KaloCyte's Products & Differentiation

See KaloCyte's products and how their products differentiate from alternatives and competitors

  • ErythroMer

    Pre-clinical stage development of an artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage and used as a universal option for treatment of severe bleeding by EMS or battlefield medics when stored blood is unavailable, undesirable or in short supply.


    ErythroMer is a universal option for all blood types and can be freeze dried for long term storage. Its design solves the know issues that were the downfall of other attempts (HBOCs and Perfluorocar… 

Expert Collections containing KaloCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KaloCyte is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

KaloCyte Patents

KaloCyte has filed 2 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Biochemistry
  • Body fluids
patents chart

Application Date

Grant Date


Related Topics



Phospholipids, Biochemistry, Nucleotides, Membrane biology, Organophosphates


Application Date


Grant Date


Related Topics

Phospholipids, Biochemistry, Nucleotides, Membrane biology, Organophosphates



Latest KaloCyte News

Synthetic Blood Substitutes Market Set for Explosive Growth rate (CAGR) of 18.5% by 2027

Sep 6, 2022

According to a recent estimate by Emergen Research, the market for synthetic blood substitutes worldwide is expected to reach USD 15.40 billion by 2027. Due to their expanding use in conditions such as cardiovascular disease, anemia, malignant neoplasm, injuries, neonatal conditions, maternal conditions, organ transplants, and other conditions, synthetic blood substitutes like Hemopure, Oxyglobin, and Hemotech are experiencing double-digit market growth. Additionally, the need for artificial blood replacements is likely to be fueled by obstetric issues associated with blood transfusions that, if improperly managed, can lead to health complications and even death. For critically unwell patients, artificial blood or blood is utilized as a red blood cell substitute. The only function of artificial blood is to deliver oxygen and carbon dioxide to the body. The component is not fully capable of performing the functions of a red blood cell. In the upcoming year, the market is anticipated to be driven by the rising need for blood transfusions. In addition, efforts to produce effective artificial oxygen carriers for the human body are growing. For instance, American Chemical Society researchers attempted to create synthetic red blood cells in June 2020 that replicate natural ones’ functions. These are the main trends that are now in the industry. One of the major factors impacting the growth of the industry is the lack of human blood for transfusions. A surgical procedure or traumatic injury results in the need for transfusions for more than 4.5 million Americans each year, and the demand for transfusions is outpacing the supply. The Pacific Heart, Lung, and Blood Institute reports that there is a severe shortage of human blood that can be used for medical procedures. In their lifetime, around 33.0% of Americans are predicted to require a transfusion due to a serious life-threatening condition. Since current projections do not account for the need for blood in situations of major civilian fatalities, terrorist attacks, and conflicts, which would drive market demand, the shortage in the coming years could be severe. Some Key Highlights from the Report : In September 2019, KaloCyte, a preclinical-stage biotech company working on creating a synthetic RBC replacement for use in situations where stored RBCs are not available, formed an association with Baltimore’s expanding biotech scene as a member of the University of Maryland (UM) BioPark. The hemoglobin obtained from a particular strain of E. coli bacterium is used to make synthetic hemoglobin-based replacements. In comparison to RBCs, the modified hemoglobin is more stable and has a better oxygen-carrying capacity. Low hemoglobin levels, percutaneous coronary intervention, coronary artery bypass grafting, non-ST-segment elevation acute coronary syndromes, and other conditions frequently require the administration of blood transfusions to patients. Thus, cardiovascular illnesses constitute a prominent application area for the market. The market for artificial blood substitutes is growing as a result of increasing strategic efforts by key market players to raise consumer awareness of these products. The artificial blood replacements market also offers you a thorough study of each country’s market growth. Additionally, it gives specific information about the positioning of market participants geographically. The historical timeframe for the data is from 2010 to 2019. Key participants include Hemarina, Sagart Corporation, FLUORO2 Therapeutics, Biopure Corporation, Alpha Therapeutic Corporation, KaloCyte, Baxter, Green Cross Corporation, North Field Laboratories, and Alliance Pharmaceutical Corporation, among others. Emergen Research has segmented the global synthetic blood substitutes market based on source, type, application, end-user, and region: Source Outlook (Revenue, USD Billion; 2017-2027) Human Blood Hemoglobin-Based Oxygen Carriers (HBOCs) Cardiovascular Diseases Hospitals & Clinics North America

KaloCyte Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KaloCyte Rank

  • When was KaloCyte founded?

    KaloCyte was founded in 2016.

  • Where is KaloCyte's headquarters?

    KaloCyte's headquarters is located at 670 W Baltimore St, Baltimore.

  • What is KaloCyte's latest funding round?

    KaloCyte's latest funding round is Unattributed.

  • How much did KaloCyte raise?

    KaloCyte raised a total of $6.1M.

  • Who are the investors of KaloCyte?

    Investors of KaloCyte include New York Blood Center, Maryland Momentum Fund, U.S. Department of Defense, National Heart Lung and Blood Institute and St. Louis Arch Angels.

  • What products does KaloCyte offer?

    KaloCyte's products include ErythroMer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.